REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026

For research purposes only. Full disclaimer →

Research/Paper
Back to Research Library
PubMedRandomized Controlled Trial

Safety and Efficacy of Liraglutide, 3.0 mg, Once Daily vs Placebo in Patients With Poor Weight Loss Following Metabolic Surgery: The BARI-OPTIMISE Randomized Clinical Trial.

Mok Jessica, Adeleke Mariam O, Brown Adrian, Magee Cormac G, Firman Chloe, Makahamadze Christwishes, Jassil Friedrich C, Marvasti Parastou, Carnemolla Alisia, Devalia Kalpana
JAMA surgery2023DOI: 10.1001/jamasurg.2023.2930

Citations

0

Subjects

Non-Human

Study Context

Randomized controlled trials are the gold standard for evaluating treatment efficacy. The randomized design minimizes bias, making findings more reliable for clinical decision-making.

Why This Matters

This research contributes to the growing body of evidence on liraglutide. Understanding the mechanisms and clinical applications of these peptides is an active area of investigation.

Citation

Mok Jessica, Adeleke Mariam O, Brown Adrian et al.. (2023). Safety and Efficacy of Liraglutide, 3.0 mg, Once Daily vs Placebo in Patients With Poor Weight Loss Following Metabolic Surgery: The BARI-OPTIMISE Randomized Clinical Trial.. JAMA surgery. https://doi.org/10.1001/jamasurg.2023.2930

View full text on PubMed

This content is derived from peer-reviewed research for educational purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider before using any peptide-based therapy.